Ariel Berger, MPH, Senior Research Scientist and US Director of Real-World Evidence at Evidera.

Ariel Berger

MPH, Senior Research Scientist and U.S. Director, Real-World Evidence

Ariel serves as a principal investigator at Evidera and has experience across a wide range of therapeutic areas, including but not limited to pulmonary arterial hypertension, infectious disease, osteoarthritis, neuropathic pain, fibromyalgia, migraine headache, mental health disorders, and end stage renal disease.

Prior to joining Evidera, Ariel was a senior consultant with Policy Analysis Inc. in Boston for about 13 years, during which time he led numerous outcomes research studies, including retrospective database analyses; developed health economic models (both budgetary impact and cost-effectiveness models); performed literature reviews; and prepared product dossiers.

His work has been published in peer-reviewed journals including Surgical Infections, Pain Practice, Journal of Health and Productivity, American Journal of Managed Care, Infection Control and Hospital Epidemiology, Annals of Pharmacotherapy, and BMC Pulmonary Medicine. His work also has been presented at multiple conferences such as the American Thoracic Society (ATS), the European Society of Clinical Microbiology and Infectious Diseases (ECMID), the American Society of Nephrology (ASN), the Infectious Diseases Society of America (IDSA), and the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Ariel has a master’s in public health with a concentration in epidemiology and biostatistics from Boston University School of Public Health and a bachelor’s from Syracuse University.